|
US7427689B2
(en)
|
2000-07-28 |
2008-09-23 |
Georgetown University |
ErbB-2 selective small molecule kinase inhibitors
|
|
WO2002053558A1
(en)
|
2001-01-02 |
2002-07-11 |
F.Hoffman-La Roche Ag |
Quinazolone derivatives as alpha 1a/b adrenergic receptor antagonists
|
|
US7105667B2
(en)
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
WO2002088079A2
(en)
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
|
EP2289942B1
(en)
|
2002-04-10 |
2013-07-31 |
Genentech, Inc. |
Anti-HER2 antibody variants
|
|
BRPI0511741A
(pt)
|
2004-06-04 |
2008-01-02 |
Astrazeneca Ab |
derivado de quinazolina ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, processo para a preparação de um derivado de quinazolina ou de um sal farmaceuticamente aceitável do mesmo
|
|
DK1771482T3
(da)
|
2004-07-22 |
2014-10-20 |
Genentech Inc |
HER2-antistofsammensætning
|
|
US7812022B2
(en)
|
2004-12-21 |
2010-10-12 |
Glaxosmithkline Llc |
2-pyrimidinyl pyrazolopyridine ErbB kinase inhibitors
|
|
CA2646257A1
(en)
|
2005-04-14 |
2006-10-26 |
Wyeth |
Use of an epidermal growth factor receptor kinase inhibitor (egfr) in gefitinib resistant patients
|
|
DK1951759T3
(da)
|
2005-11-12 |
2010-05-10 |
Lilly Co Eli |
Anti-EGFR-antistoffer
|
|
WO2007063293A1
(en)
|
2005-12-02 |
2007-06-07 |
Astrazeneca Ab |
Quinazoleine derivatives used as inhibitors of erbb tyrosine kinase
|
|
AR056857A1
(es)
|
2005-12-30 |
2007-10-24 |
U3 Pharma Ag |
Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
|
|
US20080051387A1
(en)
|
2006-06-09 |
2008-02-28 |
Yuelian Xu |
Tetrahydropyrido[3,4-d]pyrimidines and related analogues
|
|
WO2008009078A2
(en)
|
2006-07-20 |
2008-01-24 |
Gilead Sciences, Inc. |
4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
|
|
WO2008027236A2
(en)
|
2006-08-30 |
2008-03-06 |
Genentech, Inc. |
Multispecific antibodies
|
|
AU2007296746B2
(en)
|
2006-09-11 |
2012-07-05 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
EP2061469B8
(en)
|
2006-09-11 |
2014-02-26 |
Curis, Inc. |
Quinazoline based egfr inhibitors
|
|
US7547781B2
(en)
|
2006-09-11 |
2009-06-16 |
Curis, Inc. |
Quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
US8242080B2
(en)
|
2006-10-13 |
2012-08-14 |
The Regents Of The University Of California |
Inhibitors of the EGFR kinase targeting the asymmetric activating dimer interface
|
|
EP2518063B1
(en)
|
2006-12-21 |
2017-02-01 |
Sloan-Kettering Institute For Cancer Research |
Pyridazinones and furan-containing compounds
|
|
WO2008103470A2
(en)
|
2007-02-21 |
2008-08-28 |
Trustees Of Columbia University In The City Of New York |
Oncogenic-ras-signal dependent lethal compounds
|
|
PL2182948T3
(pl)
|
2007-07-24 |
2013-07-31 |
Novartis Ag |
Zastosowanie imidazochinolin do leczenia chorób EGFR-zależnych albo chorób wykazujących nabytą oporność wobec środków ukierunkowanych na członków rodziny EGFR
|
|
US8119616B2
(en)
|
2007-09-10 |
2012-02-21 |
Curis, Inc. |
Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
|
|
EP2199419B1
(en)
|
2007-10-03 |
2018-03-07 |
Nippon Steel & Sumitomo Metal Corporation |
Austenitic stainless steel
|
|
US20100298289A1
(en)
|
2007-10-09 |
2010-11-25 |
Ucb Pharma, S.A. |
Heterobicyclic compounds as histamine h4-receptor antagonists
|
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
|
US20110033453A1
(en)
|
2008-03-05 |
2011-02-10 |
Carlos Garcia-Echeverria |
Use of pyrimidine derivatives for the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
|
|
CA2729045A1
(en)
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
US8642991B2
(en)
|
2008-11-11 |
2014-02-04 |
Samsung Electronics Co., Ltd. |
Photosensitive quantum dot, composition comprising the same and method of forming quantum dot-containing pattern using the composition
|
|
US20100143295A1
(en)
|
2008-12-05 |
2010-06-10 |
Auspex Pharmaceuticals, Inc. |
Quinazoline inhibitors of egfr tyrosine kinase
|
|
WO2010099186A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Her2 antibody compositions
|
|
WO2010120996A1
(en)
|
2009-04-17 |
2010-10-21 |
Wyeth Llc |
5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine compounds, their use as mtor kinase and pi3 kinase inhibitors, and their syntheses
|
|
JP2012524800A
(ja)
|
2009-04-22 |
2012-10-18 |
ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ |
モノアシルグリセロールリパーゼ阻害剤としてのアゼチジニルジアミド
|
|
US9908884B2
(en)
|
2009-05-05 |
2018-03-06 |
Dana-Farber Cancer Institute, Inc. |
EGFR inhibitors and methods of treating disorders
|
|
CA2783743C
(en)
*
|
2009-12-11 |
2022-10-04 |
Wyeth Llc |
Phosphatidylinositol-3-kinase pathway biomarkers
|
|
EP2513148B1
(en)
|
2009-12-16 |
2016-08-31 |
AbbVie Biotherapeutics Inc. |
Anti-her2 antibodies and their uses
|
|
EP2518064A1
(en)
|
2009-12-25 |
2012-10-31 |
Mochida Pharmaceutical Co., Ltd. |
Novel aryl urea derivative
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
US20120107304A1
(en)
*
|
2010-04-27 |
2012-05-03 |
Boehringer Ingelheim International Gmbh |
Combination therapy in treatment of oncological and fibrotic diseases
|
|
WO2011140338A1
(en)
|
2010-05-05 |
2011-11-10 |
Gatekeeper Pharmaceuticals, Inc. |
Compounds that modulate egfr activity and methods for treating or preventing conditions therewith
|
|
CA2800769C
(en)
|
2010-05-27 |
2021-11-02 |
Genmab A/S |
Monoclonal antibodies against her2 epitope
|
|
US9051370B2
(en)
|
2010-08-10 |
2015-06-09 |
Glycotope Gmbh |
Humanized EGFR antibodies
|
|
AU2011290672B2
(en)
|
2010-08-20 |
2015-07-09 |
Novartis Ag |
Antibodies for epidermal growth factor receptor 3 (HER3)
|
|
MX360157B
(es)
|
2010-11-08 |
2018-10-24 |
Novartis Ag |
Uso de derivados de 2-carboxamida-cicloamino-urea en el tratamiento de enfermedades dependientes de egfr o de enfermedades que han adquirido resistencia a los agentes que tienen como objetivo los miembros de la familia egfr.
|
|
WO2012064706A1
(en)
|
2010-11-10 |
2012-05-18 |
Avila Therapeutics, Inc. |
Mutant-selective egfr inhibitors and uses thereof
|
|
EP2704572B1
(en)
|
2011-05-04 |
2015-12-30 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
US8691231B2
(en)
|
2011-06-03 |
2014-04-08 |
Merrimack Pharmaceuticals, Inc. |
Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
|
|
DK2797957T3
(da)
|
2011-11-23 |
2019-09-23 |
Medimmune Llc |
Bindingsmolekyler specifikke for her3 og anvendelser deraf
|
|
EP3590538A1
(en)
|
2011-12-05 |
2020-01-08 |
Novartis AG |
Antibodies for epidermal growth factor receptor 3 (her3)
|
|
HUE033245T2
(hu)
|
2011-12-19 |
2017-11-28 |
Synimmune Gmbh |
Bispecifikus ellenanyag molekula
|
|
US9034885B2
(en)
|
2012-01-13 |
2015-05-19 |
Acea Biosciences Inc. |
EGFR modulators and uses thereof
|
|
BR112014024131A2
(pt)
|
2012-03-29 |
2017-07-25 |
Shire Human Genetic Therapies |
lipídios catiônicos ionizáveis
|
|
EP2836482B1
(en)
|
2012-04-10 |
2019-12-25 |
The Regents of The University of California |
Compositions and methods for treating cancer
|
|
CN102659692B
(zh)
|
2012-05-04 |
2014-04-09 |
郑州泰基鸿诺药物科技有限公司 |
双联厄洛替尼及其制备方法
|
|
WO2013169401A1
(en)
|
2012-05-05 |
2013-11-14 |
Ariad Pharmaceuticals, Inc. |
Compounds for inhibiting cell proliferation in egfr-driven cancers
|
|
US9670213B2
(en)
|
2012-05-14 |
2017-06-06 |
East China University Of Science And Technology |
Pteridine ketone derivative and applications thereof as EGFR, BLK, and FLT3 inhibitor
|
|
TWI641619B
(zh)
|
2012-06-25 |
2018-11-21 |
美商再生元醫藥公司 |
抗－ｅｇｆｒ抗體及其用途
|
|
US9695133B2
(en)
|
2012-07-13 |
2017-07-04 |
The Trustees Of Columbia University In The City Of New York |
Quinazolinone-based oncogenic-RAS-selective lethal compounds and their use
|
|
BR112014032169A2
(pt)
|
2012-07-18 |
2017-08-01 |
Glycotope Gmbh |
tratamentos terapêuticos com anticorpos anti-her2 tendo uma fucosilação baixa
|
|
AR093778A1
(es)
|
2012-11-08 |
2015-06-24 |
Hoffmann La Roche |
PROTEINAS LIGANTES DE ANTIGENO ANTI-HER3/HER4 DE UNION A LA HORQUILLA b DE HER3 Y A LA HORQUILLA b DE HER4
|
|
MA38165A1
(fr)
|
2012-11-08 |
2018-07-31 |
Hoffmann La Roche |
Protéines de liaison à l'antigène her3 se liant à l'épingle à cheveux beta de her3
|
|
WO2014081718A1
(en)
|
2012-11-20 |
2014-05-30 |
Genentech, Inc. |
Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants
|
|
MX361088B
(es)
|
2012-11-21 |
2018-11-26 |
Janssen Biotech Inc |
Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
|
|
US20170275367A1
(en)
|
2012-11-21 |
2017-09-28 |
Janssen Biotech, Inc. |
Bispecific EGFR/C-Met Antibodies
|
|
CN103333246B
(zh)
|
2012-12-21 |
2015-09-16 |
百奥泰生物科技(广州)有限公司 |
一种抗egfr受体的肿瘤生长抑制剂及其制备方法和用途
|
|
WO2014137577A1
(en)
|
2013-03-08 |
2014-09-12 |
United Technologies Corporation |
Ring-shaped compliant support
|
|
US9725520B2
(en)
|
2013-03-14 |
2017-08-08 |
The Board Of Regents Of The University Of Texas System |
HER3 specific monoclonal antibodies for diagnostic and therapeutic use
|
|
US9745319B2
(en)
|
2013-03-15 |
2017-08-29 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the GTPase K-Ras G12C
|
|
MX2015012549A
(es)
|
2013-03-15 |
2016-06-21 |
Abbvie Deutschland |
Formulaciones de conjugado anticuerpo anti-egfr-farmaco.
|
|
CA2904393A1
(en)
|
2013-03-15 |
2014-09-25 |
Araxes Pharma Llc |
Covalent inhibitors of kras g12c
|
|
US9227978B2
(en)
|
2013-03-15 |
2016-01-05 |
Araxes Pharma Llc |
Covalent inhibitors of Kras G12C
|
|
WO2014210354A1
(en)
|
2013-06-28 |
2014-12-31 |
Genentech, Inc. |
Azaindazole compounds as inhibitors of t790m containing egfr mutants
|
|
EP3055290B1
(en)
|
2013-10-10 |
2019-10-02 |
Araxes Pharma LLC |
Inhibitors of kras g12c
|
|
JO3805B1
(ar)
|
2013-10-10 |
2021-01-31 |
Araxes Pharma Llc |
مثبطات كراس جي12سي
|
|
DK3092256T3
(da)
|
2014-01-10 |
2022-06-20 |
Birdie Biopharmaceuticals Inc |
Forbindelser og sammensætninger til immunterapi
|
|
NO2718543T3
(https=)
|
2014-02-04 |
2018-01-06 |
|
|
|
JP6568926B2
(ja)
|
2014-03-20 |
2019-08-28 |
カペラ セラピューティクス，インコーポレーテッド |
癌の治療のためのｅｒｂｂチロシンキナーゼ阻害剤としてのベンゾイミダゾール誘導体
|
|
CA2943220C
(en)
|
2014-03-20 |
2024-01-16 |
Capella Therapeutics, Inc. |
Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer
|
|
KR102399028B1
(ko)
|
2014-03-21 |
2022-05-17 |
엑스-바디 인코포레이티드 |
이중-특이적 항원-결합 폴리펩티드
|
|
AR099812A1
(es)
|
2014-03-21 |
2016-08-17 |
Abbvie Inc |
Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
|
|
KR102445502B1
(ko)
|
2014-04-10 |
2022-09-21 |
다이이찌 산쿄 가부시키가이샤 |
항her3 항체-약물 콘주게이트
|
|
MA40074A
(fr)
|
2014-05-30 |
2015-12-03 |
Univ Columbia |
Composés liant ras multivalents
|
|
EP3613433B1
(en)
|
2014-05-30 |
2022-01-05 |
Shanghai Henlius Biotech, Inc. |
Anti-epidermal growth factor receptor (egfr) antibodies
|
|
KR102486180B1
(ko)
|
2014-06-06 |
2023-01-11 |
레드우드 바이오사이언스 인코포레이티드 |
항-her2 항체-메이탄신 컨쥬게이트 및 이것의 사용 방법
|
|
AU2015277100A1
(en)
|
2014-06-20 |
2017-02-02 |
Abgenomics International Inc. |
HER2 antibody-drug conjugates
|
|
WO2016025650A1
(en)
|
2014-08-13 |
2016-02-18 |
Celgene Avilomics Research, Inc. |
Combinations of an erk inhibitor and a cdk4/6 inhibitor and related methods
|
|
LT3191135T
(lt)
|
2014-09-12 |
2020-11-25 |
Genentech, Inc. |
Anti-her2 antikūnai ir imunokonjugatai
|
|
JP6214790B2
(ja)
|
2014-09-16 |
2017-10-18 |
イース チャーム リミテッド |
抗ｅｇｆｒ抗体および同抗体の使用法
|
|
JO3556B1
(ar)
*
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
|
JP2017528498A
(ja)
|
2014-09-25 |
2017-09-28 |
アラクセス ファーマ エルエルシー |
Ｋｒａｓ ｇ１２ｃ変異体タンパク質のインヒビター
|
|
HUE054848T2
(hu)
|
2014-10-13 |
2021-09-28 |
Yuhan Corp |
Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
|
|
EP3209334A2
(en)
|
2014-10-20 |
2017-08-30 |
Igenica Biotherapeutics, Inc. |
Novel antibody-drug conjugates and related compounds, compositions, and methods of use
|
|
US9862712B2
(en)
|
2014-11-20 |
2018-01-09 |
Council Of Scientific & Industrial Research |
Benzimidazole based EGFR inhibitors
|
|
JP6709786B2
(ja)
|
2014-12-11 |
2020-06-17 |
ベータ ファーマ，インコーポレイテッド |
Ｅｇｆｒモジュレーターとしての置換２−アミノピリミジン誘導体
|
|
WO2016105525A2
(en)
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Novel pyrimidines as egfr inhibitors and methods of treating disorders
|
|
CN104530063B
(zh)
|
2015-01-13 |
2017-01-18 |
北京赛特明强医药科技有限公司 |
喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
|
|
EP3253750B1
(en)
|
2015-02-03 |
2019-04-10 |
Council of Scientific and Industrial Research |
Novel flavone based egfr inhibitors and process for preparation thereof
|
|
CA2974442A1
(en)
|
2015-02-03 |
2016-08-11 |
Trillium Therapeutics Inc. |
Novel fluorinated derivatives as egfr inhibitors useful for treating cancers
|
|
US10017540B2
(en)
|
2015-03-11 |
2018-07-10 |
California Institute Of Technology |
Cyclic peptide binder against oncogenic K-Ras
|
|
ES2898765T3
(es)
|
2015-04-10 |
2022-03-08 |
Araxes Pharma Llc |
Compuestos de quinazolina sustituidos y métodos de uso de los mismos
|
|
US10428064B2
(en)
|
2015-04-15 |
2019-10-01 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of KRAS and methods of use thereof
|
|
US10421764B2
(en)
|
2015-04-24 |
2019-09-24 |
H. Lee Moffitt Cancer Center And Research Institute, Inc. |
Mutant KRas inhibitors
|
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
|
AU2016258192B2
(en)
|
2015-05-06 |
2021-07-29 |
Leidos Biomedical Research, Inc. |
K-Ras modulators
|
|
US10144724B2
(en)
|
2015-07-22 |
2018-12-04 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use thereof
|
|
CN108513588A
(zh)
|
2015-09-24 |
2018-09-07 |
Ionis制药公司 |
Kras表达的调节剂
|
|
EP3356347A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058805A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3356349A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017058728A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
WO2017070256A2
(en)
|
2015-10-19 |
2017-04-27 |
Araxes Pharma Llc |
Method for screening inhibitors of ras
|
|
EP3365686A4
(en)
|
2015-10-22 |
2019-03-27 |
The Scripps Research Institute |
REACTIVE CYSTEINSONS AND USES THEREOF
|
|
WO2017080980A1
(en)
|
2015-11-09 |
2017-05-18 |
Astrazeneca Ab |
Dihydropyrrolopyrazinone derivatives useful in the treatment of cancer
|
|
WO2017079864A1
(en)
|
2015-11-12 |
2017-05-18 |
Hangzhou Yier Biotech Co., Ltd. |
Treatment of cancers related to chronically active ras
|
|
KR20180081596A
(ko)
|
2015-11-16 |
2018-07-16 |
아락세스 파마 엘엘씨 |
치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법
|
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
|
US20170283445A1
(en)
|
2016-04-05 |
2017-10-05 |
University Of South Carolina |
Small Molecule Inhibitors Selective For Polo-Like Kinase Proteins
|
|
KR102444509B1
(ko)
*
|
2016-05-18 |
2022-09-19 |
미라티 테라퓨틱스, 인크. |
Kras g12c 억제제
|
|
MX383920B
(es)
|
2016-05-26 |
2025-03-14 |
Recurium Ip Holdings Llc |
Compuestos inhibidores de egfr.
|
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
|
US10377833B2
(en)
|
2016-07-22 |
2019-08-13 |
Beijing Mabworks Biotech Co., Ltd. |
Bispecific anti-HER2 antibody
|
|
BR112019005001A2
(pt)
|
2016-09-15 |
2019-06-04 |
Universität Stuttgart |
proteína de ligação ao antígeno, proteína de fusão, ácido nucleico, vetor recombinante, célula hospedeira recombinante, composição farmacêutica, uso médico da proteína de ligação ao antígeno e método de inibição do crescimento tumoral
|
|
WO2018064510A1
(en)
|
2016-09-29 |
2018-04-05 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
|
EP3523289A1
(en)
|
2016-10-07 |
2019-08-14 |
Araxes Pharma LLC |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
|
US12150934B2
(en)
|
2016-11-30 |
2024-11-26 |
Bantam Pharmaceutical, Llc |
Methods of using substituted pyrazole and pyrazole compounds and for treatment of hyperproliferative diseases
|
|
CA3081983A1
(en)
|
2016-11-30 |
2018-06-07 |
Bantam Pharmaceutical, Llc |
Substituted pyrazole compounds and methods of using them for treatment of hyperproliferative diseases
|
|
KR20190095355A
(ko)
|
2016-12-15 |
2019-08-14 |
더 리젠츠 오브 더 유니버시티 오브 캘리포니아 |
암의 치료를 위한 조성물 및 방법
|
|
CN110366550A
(zh)
|
2016-12-22 |
2019-10-22 |
美国安进公司 |
作为用于治疗肺癌、胰腺癌或结直肠癌的KRAS G12C抑制剂的苯并异噻唑、异噻唑并[3,4-b]吡啶、喹唑啉、酞嗪、吡啶并[2,3-d]哒嗪和吡啶并[2,3-d]嘧啶衍生物
|
|
EP3558979B1
(en)
|
2016-12-22 |
2021-02-17 |
Boehringer Ingelheim International GmbH |
Novel benzylamino substituted quinazolines and derivatives as sos1 inhibitors
|
|
US10344026B2
(en)
|
2017-01-18 |
2019-07-09 |
Nantbio, Inc. |
Compositions and methods of targeting mutant K-ras
|
|
JP7327802B2
(ja)
|
2017-01-26 |
2023-08-16 |
アラクセス ファーマ エルエルシー |
縮合ヘテロ－ヘテロ二環式化合物およびその使用方法
|
|
WO2018140599A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
Benzothiophene and benzothiazole compounds and methods of use thereof
|
|
EP3573966A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused n-heterocyclic compounds and methods of use thereof
|
|
WO2018140513A1
(en)
|
2017-01-26 |
2018-08-02 |
Araxes Pharma Llc |
1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
|
|
US11136308B2
(en)
|
2017-01-26 |
2021-10-05 |
Araxes Pharma Llc |
Substituted quinazoline and quinazolinone compounds and methods of use thereof
|
|
EP3573954A1
(en)
|
2017-01-26 |
2019-12-04 |
Araxes Pharma LLC |
Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
|
|
JOP20190186A1
(ar)
|
2017-02-02 |
2019-08-01 |
Astellas Pharma Inc |
مركب كينازولين
|
|
EP3612526A2
(en)
|
2017-04-20 |
2020-02-26 |
The Regents of the University of California |
K-ras modulators
|
|
AU2018329920B2
(en)
|
2017-09-08 |
2022-12-01 |
Amgen Inc. |
Inhibitors of KRAS G12C and methods of using the same
|
|
LT3710439T
(lt)
*
|
2017-11-15 |
2023-05-10 |
Mirati Therapeutics, Inc. |
Kras g12c inhibitoriai
|
|
US10647715B2
(en)
*
|
2017-11-15 |
2020-05-12 |
Mirati Therapeutics, Inc. |
KRas G12C inhibitors
|
|
EP3832583A4
(en)
|
2018-07-31 |
2021-12-08 |
Honda Motor Co., Ltd. |
PERFORMANCE FORECAST SYSTEM, PERFORMANCE FORECAST DEVICE, PERFORMANCE FORECAST METHOD, PROGRAM AND STORAGE MEDIUM
|
|
EP3849537B1
(en)
*
|
2018-09-10 |
2024-10-23 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
ES3017461T3
(en)
*
|
2018-09-10 |
2025-05-13 |
Mirati Therapeutics Inc |
Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer
|
|
JP2022500385A
(ja)
*
|
2018-09-10 |
2022-01-04 |
ミラティ セラピューティクス， インコーポレイテッド |
組み合わせ療法
|
|
EP3849535A4
(en)
*
|
2018-09-10 |
2022-06-29 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
CN109413550B
(zh)
|
2018-09-30 |
2021-03-09 |
华为技术有限公司 |
音频播放电路和终端
|
|
CN111193490B
(zh)
|
2018-11-14 |
2025-05-13 |
天津大学 |
散热结构、带散热结构的体声波谐振器、滤波器和电子设备
|
|
MX2021002804A
(es)
*
|
2018-12-05 |
2021-07-15 |
Mirati Therapeutics Inc |
Terapias de combinacion.
|
|
EP3908283A4
(en)
|
2019-01-10 |
2022-10-12 |
Mirati Therapeutics, Inc. |
KRAS G12C INHIBITORS
|
|
US20220193242A1
(en)
|
2019-02-07 |
2022-06-23 |
The Regents Of The University Of California |
Immunophilin-dependent inhibitors and uses thereof
|
|
US20220221355A1
(en)
|
2019-02-11 |
2022-07-14 |
Mesomat Inc. |
Sensing fibers for structural health monitoring
|
|
KR102747104B1
(ko)
|
2019-02-18 |
2024-12-27 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리도[3,4-d]피리미딘-8-온 유도체 및 이를 포함하는 암의 예방, 개선 또는 치료용 약학 조성물
|
|
CN114026116A
(zh)
|
2019-02-20 |
2022-02-08 |
弗雷德哈钦森癌症研究中心 |
Ras新抗原特异性结合蛋白及其用途
|
|
GB201902392D0
(en)
|
2019-02-21 |
2019-04-10 |
Cambridge Entpr Ltd |
Modular binding proteins
|
|
WO2020176693A2
(en)
|
2019-02-26 |
2020-09-03 |
Cell Response, Inc. |
Methods for treating map3k8 positive cancers
|
|
WO2020177629A1
(zh)
|
2019-03-01 |
2020-09-10 |
劲方医药科技(上海)有限公司 |
螺环取代的嘧啶并环类化合物，其制法与医药上的用途
|
|
KR102934231B1
(ko)
|
2019-03-05 |
2026-03-06 |
아스트라제네카 아베 |
항암제로 유용한 융합 삼환식 화합물
|
|
US12117170B2
(en)
|
2019-03-05 |
2024-10-15 |
Questor Technology Inc. |
Gas incinerator system
|
|
EP3941938A1
(en)
|
2019-03-06 |
2022-01-26 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
US20220160714A1
(en)
|
2019-03-22 |
2022-05-26 |
Icahn School Of Medicine At Mount Sinai |
Methods for treating colorectal cancer
|
|
BR112021018739A2
(pt)
|
2019-03-29 |
2022-05-03 |
Dicerna Pharmaceuticals Inc |
Composições e métodos para o tratamento de doenças ou distúrbios associados a kras
|
|
CA3134825A1
(en)
|
2019-03-29 |
2020-10-08 |
Kura Oncology, Inc. |
Methods of treating squamous cell carcinomas with farnesyltransferase inhibitors
|
|
KR102222693B1
(ko)
|
2019-04-04 |
2021-03-04 |
금정제약 주식회사 |
H-rev107 유래 펩타이드의 신규한 용도
|
|
WO2020214537A1
(en)
|
2019-04-15 |
2020-10-22 |
Tosk, Inc. |
Modulators of ras gtpase
|
|
US20200335182A1
(en)
|
2019-04-16 |
2020-10-22 |
Uratim Ltd. |
Method and apparatus for facilitating the binding of biological macromolecules with the use of gluing molecular agents with applications in RAS mutations and related conditions
|
|
KR20220012255A
(ko)
|
2019-04-28 |
2022-02-03 |
젠플리트 테라퓨틱스 (상하이) 아이엔씨. |
옥사아자퀴나졸린-7(8h)-케톤 화합물, 이의 제조 방법 및 이의 약학적 응용
|
|
US11518758B2
(en)
|
2019-05-10 |
2022-12-06 |
Deciphera Pharmaceuticals, Llc |
Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
|
|
PE20220597A1
(es)
|
2019-05-10 |
2022-04-22 |
Deciphera Pharmaceuticals Llc |
Inhibidores de la autofagia de fenilaminopirimidina amida y metodos de uso de estos
|
|
EP3969449B1
(en)
|
2019-05-13 |
2025-02-12 |
Novartis AG |
New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl)isonicotinamide as raf inhibitors for the treatment of cancer
|
|
US11879013B2
(en)
|
2019-05-14 |
2024-01-23 |
Janssen Biotech, Inc. |
Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors
|
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
|
JP7502337B2
(ja)
|
2019-05-20 |
2024-06-18 |
カリフォルニア インスティチュート オブ テクノロジー |
Ｋｒａｓ ｇ１２ｃインヒビター及びその使用
|
|
CN114437065A
(zh)
|
2019-05-21 |
2022-05-06 |
益方生物科技(上海)股份有限公司 |
杂环化合物，其制备方法和用途
|
|
AU2020277398B2
(en)
|
2019-05-21 |
2026-01-29 |
Amgen Inc. |
Solid state forms
|
|
WO2020234103A1
(en)
|
2019-05-21 |
2020-11-26 |
Bayer Aktiengesellschaft |
Identification and use of kras inhibitors
|
|
WO2020236947A1
(en)
|
2019-05-21 |
2020-11-26 |
Amgen Inc. |
Solid state forms
|
|
US12577278B2
(en)
|
2019-06-07 |
2026-03-17 |
Emory University |
KRAS G12V mutant binds to JAK1, inhibitors, pharmaceutical compositions, and methods related thereto
|
|
CN114269715A
(zh)
|
2019-06-12 |
2022-04-01 |
范德比尔特大学 |
作为氨基酸转运抑制剂的二苄基胺
|
|
CA3141405A1
(en)
|
2019-06-12 |
2020-12-17 |
H. Charles Manning |
Amino acid transport inhibitors and the uses thereof
|
|
WO2021000885A1
(zh)
|
2019-07-01 |
2021-01-07 |
江苏恒瑞医药股份有限公司 |
喹唑啉酮类衍生物、其制备方法及其在医药上的应用
|
|
JP7756069B6
(ja)
|
2019-08-02 |
2025-11-27 |
上海済▲ユウ▼医薬科技股▲フン▼有限公司 |
四環式化合物、その調製と使用の方法
|
|
CN112341457A
(zh)
|
2019-08-07 |
2021-02-09 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
CN114174298B
(zh)
|
2019-08-14 |
2023-08-01 |
正大天晴药业集团南京顺欣制药有限公司 |
哒嗪酮并嘧啶类衍生物及其医药用途
|
|
CN112390797A
(zh)
|
2019-08-15 |
2021-02-23 |
微境生物医药科技(上海)有限公司 |
新型螺环类K-Ras G12C抑制剂
|
|
WO2021031952A1
(zh)
|
2019-08-16 |
2021-02-25 |
劲方医药科技(上海)有限公司 |
氧代六元环并嘧啶类化合物，其制法与医药上的用途
|
|
MX2022002108A
(es)
|
2019-08-22 |
2022-03-17 |
Univ Michigan Regents |
Metodo para tratar canceres asociados con kras.
|
|
CN114269735B
(zh)
|
2019-08-26 |
2024-02-23 |
南京创济生物医药有限公司 |
二氢或四氢喹唑啉类化合物及其中间体、制备方法和应用
|
|
MX2022002465A
(es)
|
2019-08-29 |
2022-05-19 |
Mirati Therapeutics Inc |
Inhibidores de kras g12d.
|
|
EP3819300A4
(en)
|
2019-09-06 |
2021-11-24 |
Wellmarker Bio Co., Ltd. |
THERAPEUTIC COMPOSITION BASED ON BIOMARKERS
|
|
WO2021043322A1
(zh)
|
2019-09-06 |
2021-03-11 |
正大天晴药业集团南京顺欣制药有限公司 |
氮杂环庚烷并嘧啶类衍生物及其医药用途
|
|
WO2021050732A1
(en)
|
2019-09-10 |
2021-03-18 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods of treating kras mutant cancers
|
|
US20230002371A1
(en)
|
2019-09-13 |
2023-01-05 |
Biotheryx, Inc. |
Ras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
|
|
US20220402916A1
(en)
|
2019-09-18 |
2022-12-22 |
Merck Sharp & Dohme Corp. |
Small molecule inhibitors of kras g12c mutant
|
|
WO2021052499A1
(zh)
|
2019-09-20 |
2021-03-25 |
上海济煜医药科技有限公司 |
稠合吡啶酮类化合物及其制备方法和应用
|
|
CN114502165A
(zh)
|
2019-09-23 |
2022-05-13 |
苏州浦合医药科技有限公司 |
Shp2抑制剂及其用途
|
|
WO2021061749A1
(en)
|
2019-09-24 |
2021-04-01 |
Mirati Therapeutics, Inc. |
Combination therapies
|
|
TW202115062A
(zh)
|
2019-09-25 |
2021-04-16 |
大陸商北京加科思新藥研發有限公司 |
Kras突變蛋白抑制劑
|
|
WO2021058018A1
(en)
|
2019-09-29 |
2021-04-01 |
Beigene, Ltd. |
Inhibitors of kras g12c
|
|
WO2021063346A1
(zh)
|
2019-09-30 |
2021-04-08 |
上海迪诺医药科技有限公司 |
Kras g12c抑制剂及其应用
|
|
CN114555586B
(zh)
|
2019-10-10 |
2023-06-23 |
信达生物制药(苏州)有限公司 |
Krasg12c蛋白抑制剂及其制备方法和用途
|
|
US20240139193A1
(en)
|
2019-10-15 |
2024-05-02 |
Amgen Inc. |
Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
|
|
JP6754125B1
(ja)
|
2019-10-15 |
2020-09-09 |
学校法人東京理科大学 |
Ｂｒａｐ２作用増強剤
|
|
CN112694475B
(zh)
|
2019-10-23 |
2025-09-23 |
苏州泽璟生物制药股份有限公司 |
环烷基类和杂环烷基类抑制剂及其制备方法和应用
|
|
US12331035B2
(en)
|
2019-10-23 |
2025-06-17 |
Sk Biopharmaceuticals Co., Ltd. |
Bicyclic compound and use thereof
|
|
EP4048671B1
(en)
|
2019-10-24 |
2026-03-18 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as kras g12c and kras g12d inhibitors in the treatment of cancer
|
|
UA129778C2
(uk)
|
2019-10-28 |
2025-07-30 |
Мерк Шарп Енд Доум Елелсі |
Низькомолекулярні інгібітори g12c-мутантного kras
|
|
JP7601869B2
(ja)
|
2019-10-30 |
2024-12-17 |
▲勁▼方医▲薬▼科技（上海）有限公司 |
置換された複素環－環系化合物、その調製方法及び医薬への応用
|
|
WO2021084765A1
(en)
|
2019-10-31 |
2021-05-06 |
Taiho Pharmaceutical Co., Ltd |
4-aminobut-2-enamide derivatives and salts thereof
|
|
US20230023023A1
(en)
|
2019-10-31 |
2023-01-26 |
Taiho Pharmaceutical Co., Ltd. |
4-aminobut-2-enamide derivatives and salts thereof
|
|
IL322454A
(en)
|
2019-11-04 |
2025-09-01 |
Revolution Medicines Inc |
ras inhibitors
|
|
AU2020377925A1
(en)
|
2019-11-04 |
2022-05-05 |
Revolution Medicines, Inc. |
Ras inhibitors
|
|
TW202132316A
(zh)
|
2019-11-04 |
2021-09-01 |
美商銳新醫藥公司 |
Ｒａｓ抑制劑
|
|
CN113286794B
(zh)
|
2019-11-04 |
2024-03-12 |
北京加科思新药研发有限公司 |
Kras突变蛋白抑制剂
|
|
BR112022007535A2
(pt)
|
2019-11-07 |
2022-07-12 |
Chugai Pharmaceutical Co Ltd |
Composto peptídico cíclico tendo ação inibitória de kras
|
|
CN112778301A
(zh)
|
2019-11-07 |
2021-05-11 |
苏州泽璟生物制药股份有限公司 |
四氢吡啶并嘧啶类抑制剂及其制备方法和应用
|
|
CN114630832A
(zh)
|
2019-11-15 |
2022-06-14 |
四川海思科制药有限公司 |
一种嘧啶并环衍生物及其在医药上的应用
|
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
|
CN113614080B
(zh)
|
2019-11-29 |
2022-06-28 |
苏州信诺维医药科技股份有限公司 |
Kras g12c抑制剂化合物及其用途
|
|
EP4067343A4
(en)
|
2019-11-29 |
2024-01-03 |
Taiho Pharmaceutical Co., Ltd. |
NEW PHENOLIC COMPOUND OR SALT THEREOF
|
|
WO2021106231A1
(en)
|
2019-11-29 |
2021-06-03 |
Taiho Pharmaceutical Co., Ltd. |
A compound having inhibitory activity against kras g12d mutation
|
|
WO2021109737A1
(zh)
|
2019-12-02 |
2021-06-10 |
上海璎黎药业有限公司 |
一种含氧杂环化合物、其制备方法及应用
|
|
WO2021113595A1
(en)
|
2019-12-06 |
2021-06-10 |
Beta Pharma, Inc. |
Phosphorus derivatives as kras inhibitors
|
|
WO2021126799A1
(en)
|
2019-12-18 |
2021-06-24 |
Merck Sharp & Dohme Corp. |
Macrocyclic peptides as potent inhibitors of k-ras g12d mutant
|
|
WO2021120045A1
(en)
|
2019-12-18 |
2021-06-24 |
InventisBio Co., Ltd. |
Heterocyclic compounds, preparation methods and uses thereof
|
|
CN114761408B
(zh)
|
2019-12-19 |
2023-09-15 |
贝达药业股份有限公司 |
Kras g12c抑制剂及其在医药上的应用
|
|
WO2021121397A1
(zh)
|
2019-12-19 |
2021-06-24 |
首药控股(北京)股份有限公司 |
取代的炔基杂环化合物
|
|
IL293962B2
(en)
|
2019-12-19 |
2025-10-01 |
Jacobio Pharmaceuticals Co Ltd |
Mutant KRAS protein inhibitors
|
|
TR201920922A2
(tr)
|
2019-12-20 |
2020-06-22 |
Ankara Ueniversitesi |
3/4-((2E,6E)-3,7,11-Trimetildodeka-2,6,10-trieniltiyo)benzamid Türevi Bileşikler
|
|
CA3164995A1
(en)
|
2019-12-20 |
2021-06-24 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
JP7850663B2
(ja)
|
2019-12-27 |
2026-04-23 |
ウィゲン・バイオメディシン・テクノロジー・（シャンハイ）・カンパニー・リミテッド |
スピロ環含有キナゾリン化合物
|
|
CN113045565A
(zh)
|
2019-12-27 |
2021-06-29 |
微境生物医药科技(上海)有限公司 |
新型K-Ras G12C抑制剂
|
|
WO2021139678A1
(zh)
|
2020-01-07 |
2021-07-15 |
广州百霆医药科技有限公司 |
吡啶并嘧啶类kras g12c突变蛋白抑制剂
|
|
WO2021139748A1
(en)
|
2020-01-08 |
2021-07-15 |
Ascentage Pharma (Suzhou) Co., Ltd. |
Spirocyclic tetrahydroquinazolines
|
|
US20210269434A1
(en)
|
2020-01-10 |
2021-09-02 |
Incyte Corporation |
Tricyclic compounds as inhibitors of kras
|
|
WO2021143693A1
(zh)
|
2020-01-13 |
2021-07-22 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
KR102396930B1
(ko)
|
2020-01-15 |
2022-05-12 |
한국과학기술연구원 |
피리도[3,4-d]피리미딘 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
KR102382613B1
(ko)
|
2020-01-15 |
2022-04-06 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물
|
|
WO2021150613A1
(en)
|
2020-01-20 |
2021-07-29 |
Incyte Corporation |
Spiro compounds as inhibitors of kras
|
|
CN115003668A
(zh)
|
2020-01-21 |
2022-09-02 |
南京明德新药研发有限公司 |
作为kras抑制剂的大环类化合物
|
|
GB202001344D0
(en)
|
2020-01-31 |
2020-03-18 |
Redx Pharma Plc |
Ras Inhibitors
|
|
CN115135650A
(zh)
|
2020-02-20 |
2022-09-30 |
贝达医药公司 |
作为kras抑制剂的吡啶并嘧啶衍生物
|
|
CN113637005B
(zh)
|
2020-02-24 |
2024-05-24 |
泰励生物科技（上海）有限公司 |
用于癌症治疗的kras抑制剂
|
|
CN114845997B
(zh)
|
2020-02-24 |
2024-03-29 |
上海喆邺生物科技有限公司 |
芳香类化合物及其在制备抗肿瘤药物中的应用
|
|
US20210292330A1
(en)
|
2020-02-28 |
2021-09-23 |
Erasca, Inc. |
Pyrrolidine-fused heterocycles
|
|
CN114901663B
(zh)
|
2020-03-02 |
2024-07-02 |
上海喆邺生物科技有限公司 |
一类芳香杂环类化合物及其在药物中的应用
|
|
KR20210111711A
(ko)
|
2020-03-03 |
2021-09-13 |
웰마커바이오 주식회사 |
Kras 돌연변이 및 활성화된 ron이 존재하는 암의 예방 또는 치료용 약학 조성물
|
|
WO2021178741A1
(en)
|
2020-03-05 |
2021-09-10 |
The Regents Of The University Of Michigan |
Inhibitors of egfr, kras, braf, and other targets and use of the same
|
|
CN115397413A
(zh)
|
2020-03-05 |
2022-11-25 |
密歇根大学董事会 |
Egfr、kras、braf和其他靶标的抑制剂及其用途
|
|
AU2021233058B2
(en)
|
2020-03-12 |
2024-05-16 |
D3 Bio(Wuxi) Co., Ltd |
Pyrimidoheterocyclic compounds and application thereof
|
|
TW202144345A
(zh)
|
2020-03-17 |
2021-12-01 |
大陸商北京加科思新藥研發有限公司 |
Ｋｒａｓ突變蛋白抑制劑
|
|
CA3170068A1
(en)
|
2020-03-25 |
2021-09-30 |
Yuli Xie |
Spiro ring-containing quinazoline compound
|
|
WO2021197499A1
(zh)
|
2020-04-03 |
2021-10-07 |
南京明德新药研发有限公司 |
八氢吡嗪并二氮杂萘啶二酮类化生物
|
|
CN115803030A
(zh)
|
2020-04-06 |
2023-03-14 |
阿维纳斯企业公司 |
用于kras靶向降解的化合物和方法
|
|
TW202144338A
(zh)
|
2020-04-08 |
2021-12-01 |
大陸商江蘇恆瑞醫藥股份有限公司 |
嘧啶并二環類衍生物、其製備方法及其在醫藥上的應用
|
|
AU2021254794A1
(en)
|
2020-04-16 |
2022-12-15 |
Incyte Corporation |
Fused tricyclic KRAS inhibitors
|
|
WO2021216770A1
(en)
|
2020-04-22 |
2021-10-28 |
Accutar Biotechnology Inc. |
Substituted tetrahydroquinazoline compounds as kras inhibitors
|
|
US20230242586A1
(en)
|
2020-04-23 |
2023-08-03 |
The Regents Of The University Of California |
Ras inhibitors and uses thereof
|
|
WO2021215544A1
(en)
|
2020-04-24 |
2021-10-28 |
Taiho Pharmaceutical Co., Ltd. |
Kras g12d protein inhibitors
|
|
CN115135636B
(zh)
|
2020-04-29 |
2024-08-23 |
北京泰德制药股份有限公司 |
喹喔啉酮衍生物作为kras g12c突变蛋白的不可逆抑制剂
|
|
CA3177261A1
(en)
|
2020-04-29 |
2021-11-04 |
Shanghai Ringene Biopharma Co., Ltd. |
Benzothiazolyl biaryl compound, and preparation method and use
|
|
WO2021219072A1
(zh)
|
2020-04-30 |
2021-11-04 |
上海科州药物研发有限公司 |
作为kras抑制剂的杂环化合物的制备及其应用方法
|
|
US11739102B2
(en)
|
2020-05-13 |
2023-08-29 |
Incyte Corporation |
Fused pyrimidine compounds as KRAS inhibitors
|
|
CN113666923A
(zh)
|
2020-05-15 |
2021-11-19 |
苏州泽璟生物制药股份有限公司 |
烷氧基烷基取代杂环基类抑制剂及其制备方法和应用
|
|
WO2021236475A1
(en)
|
2020-05-18 |
2021-11-25 |
Asinex Corporation |
Compounds that inhibit asparagine synthetase and their methods of use
|
|
TWI799871B
(zh)
|
2020-05-27 |
2023-04-21 |
大陸商勁方醫藥科技(上海)有限公司 |
三環并環類化合物，其製法與醫藥上的用途
|
|
CA3180314A1
(en)
|
2020-05-29 |
2021-12-02 |
John Graeme HODGSON |
Methods of treating cancer in patients with an anomalous kras gene or deletions within chromosome 9
|
|
JP7808058B2
(ja)
|
2020-06-02 |
2026-01-28 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
がんを治療するための縮合環化２－アミノ－３－シアノチオフェン及び誘導体
|
|
WO2021244603A1
(en)
|
2020-06-04 |
2021-12-09 |
Shanghai Antengene Corporation Limited |
Inhibitors of kras g12c protein and uses thereof
|
|
US20230202981A1
(en)
|
2020-06-04 |
2023-06-29 |
Baskaran Pillai |
Novel small molecules for targeted degradation of untargetable kras in cancer therapy
|
|
US20230023009A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248083A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248082A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
US20230026856A1
(en)
|
2020-06-05 |
2023-01-26 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021248079A1
(en)
|
2020-06-05 |
2021-12-09 |
Sparcbio Llc |
Heterocyclic compounds and methods of use thereof
|
|
WO2021252339A1
(en)
|
2020-06-08 |
2021-12-16 |
Accutar Biotechnology, Inc. |
Substituted purine-2,6-dione compounds as kras inhibitors
|
|
WO2021249563A1
(zh)
|
2020-06-12 |
2021-12-16 |
苏州泽璟生物制药股份有限公司 |
芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用
|
|
US20230227466A1
(en)
|
2020-06-18 |
2023-07-20 |
Shy Therapeutics, Llc |
Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
|
|
WO2021259331A1
(zh)
|
2020-06-24 |
2021-12-30 |
南京明德新药研发有限公司 |
八元含n杂环类化合物
|
|
WO2022002102A1
(en)
|
2020-06-30 |
2022-01-06 |
InventisBio Co., Ltd. |
Quinazoline compounds, preparation methods and uses thereof
|
|
WO2022015375A1
(en)
|
2020-07-16 |
2022-01-20 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022017339A1
(zh)
|
2020-07-20 |
2022-01-27 |
江苏恒瑞医药股份有限公司 |
稠合哒嗪类衍生物、其制备方法及其在医药上的应用
|
|
JP7584815B2
(ja)
|
2020-08-02 |
2024-11-18 |
上▲海▼▲哲▼▲イェ▼生物科技有限公司 |
抗腫瘍薬物における芳香族化合物及びその用途
|
|
EP4192585A4
(en)
|
2020-08-04 |
2024-08-21 |
Mirati Therapeutics, Inc. |
Kras g12d inhibitors
|
|
WO2022028492A1
(en)
|
2020-08-05 |
2022-02-10 |
Beigene, Ltd. |
Imidazotriazine and pyrrolopyrimidine derivatives as kras g12c inhibitors
|
|
US20230303551A1
(en)
|
2020-08-13 |
2023-09-28 |
Albert Einstein College Of Medicine |
N-cyclyl-sulfonamides useful for inhibiting raf
|
|
EP4210833A4
(en)
*
|
2020-09-11 |
2024-09-11 |
Mirati Therapeutics, Inc. |
CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR
|
|
EP4232039A4
(en)
*
|
2020-10-23 |
2024-08-14 |
Mirati Therapeutics, Inc. |
METHODS OF TREATING LUNG CANCER
|
|
WO2022216648A1
(en)
*
|
2021-04-08 |
2022-10-13 |
Mirati Therapeutics, Inc. |
Combination therapies using prmt5 inhibitors for the treatment of cancer
|